David P. Holveck, President
Johnson & Johnson Development Corp.; former CEO of Centocor
David P. Holveck is
Corporate vice president, corporate development, for Johnson &
Johnson and an officer of the Corporation. He was named to his
present position in March, 2004. In addition, Mr. Holveck serves
as president, Johnson & Johnson Development Corporation. He
was appointed to this position in March 2003.
Mr. Holveck joined the
Corporation as a company group chairman in October 1999, with the
completion of the merger of Centocor, Inc., and Johnson &
Johnson. Prior to joining Johnson & Johnson, he had been
chief executive officer of Centocor, Inc., since 1992 and a member of
its board of directors since 1994.
In 1983 Mr. Holveck
started his Centocor, Inc., career, progressing through various
executive positions. In 1992 he assumed the role of president and
chief operating officer of Centocor, Inc., and later that year was
named president and chief executive officer. In 2003 Mr. Holveck
was promoted to president, Johnson & Johnson Development
Corporation, a position he held until being named to his present
Prior to joining Centocor, Inc., he had held positions at General Electric Company, Corning Glass Works and Abbott Laboratories.
Mr. Holveck is a board member ofthe
University City Science Center in Philadelphia and the Eastern
Technology Council. He also serves on the Board of Trustees for
The Fund for West Chester University. Mr. Holveck is a former
board member of the Biotechnology Industry Organization, Pharmaceutical
Research and Manufacturing Association (PhRMA), the Board of Governors
for Pennsylvania's State System of Higher Education and the Liberty
Mr. Holveck received a
bachelor of science degree in education/science from West Chester
University. He and his wife have two daughters and five
Paul H. Keckley, Ph.D.
Executive Director of the Deloitte Center for Health Solutions
Paul H. Keckley, Ph.D.,
is Executive Director for the Deloitte Center for Health Solutions
(“the Center”), a part of Deloitte & Touche USA
LLP. He is a health economist and policy expert and brings a
distinguished 30 year career in health services research in the private
sector and academic medicine.
The Deloitte Center for
Health Solutions is an independent research organization focused on the
issues and challenges of the US health system. The Center’s
research agenda includes trending of healthcare consumerism, monitoring
of pay for performance programs, innovations in reducing the gap
between evidence and practice, enhanced methods for information
technology adoption, and models of community care coordination that
improve population-based health status while reducing costs.
Prior to joining
Deloitte, Dr. Keckley served in several key roles at Vanderbilt
University Medical Center’s senior management, including
Executive Director of the Vanderbilt Center for Evidence-based
Medicine, Associate Professor in the Vanderbilt University School of
Medicine, and Adjunct Professor of Health Management at the Owen
Graduate School of Business’ healthcare MBA and MD-MBA programs.
Vanderbilt, Dr. Keckley served as Chairman of the Board of Interdent, a
California dental practice management company; Chief Executive Officer
of EBM Solutions, a developer of evidence-based guideline software;
Chief Executive Officer of Aveta; and Principal of The Keckley Group, a
strategic planning consulting practice that served 1,200 U.S. provider
organizations and health plans.
Dr. Keckley is an
active member of several societies and editorial boards, and has
authored numerous articles and three books. He has been profiled
by ABC’s 20/20, CBS’s 60 Minutes, Fox News, CNN, and The Wall Street Journal.
Dr. Keckley received a B.A. from Lipscomb University, his MA/PhD from
Ohio State University, and completed a fellowship in economic policy at
Jim Boylan (’94)
Managing Director, Merrill Lynch
Merrill Lynch in 1997 and is currently a Managing Director in the Global
Healthcare Investment Banking Group. Prior to joining the healthcare group, Jim
was a Managing Director in Merrill Lynch’s Mergers & Acquisitions Group
specializing in Healthcare M&A. Jim has significant relationships and
transaction experience across healthcare including services, medical devices and
biotech/pharma. Recent equity experience includes the IPOs of Tomotherapy,
Insulet and NxStage, follow-on offerings for Omnicare and Celgene and
convertible offerings for MedImmune and Lincare. Jim’s M&A experience
includes NxStage's acquisition of MediSystems, Healthway's acquisition of Axia
Health, the sale of The F. Dohmen's wholesale distribution business to Cardinal
Health, the sale of CRC Health to Bain Capital, the sale of Proxima Therapeutics
to Cytyc, Advance Paradigm's acquisition of PCS HealthSystems, MedImmune's
acquisition of Aviron and Allergan's spin-off of Advanced Medical Optics. Prior
to joining Merrill Lynch, Jim was a healthcare investment banker at Smith Barney
where he completed several debt and equity financing transactions. He received a
B.S. in finance from Lehigh University in 1989 and an M.B.A. from Columbia
Business School in 1994.
Tamar Howson (’80), Executive Vice President, Business Development, Lexicon Pharmaceuticals
Tamar Howson joined
Lexicon Pharmaceuticals as Executive Vice President, Business
development in April, 2007. Between 2001 and 2007 Tamar was the
Senior Vice President of Corporate and Business Development and member
of the Executive Committee at Bristol-Myers Squibb. While at BMS, Tamar
worked on many licensing agreements and research collaborations
including partnerships with Lexicon, Medarex, Pierre-Fabre, Solvay,
Exelixis, Merck, Astra-Zeneca among others.
In 2000 and 2001 Tamar
was a business development and strategic planning consultant to
biotechnology and pharmaceutical companies, served as a Special Limited
partner at Care Capital, LLC., a Director for Ariad Pharmaceuticals,
NPS Pharmaceuticals, SkyePharma Plc., Targacept as well as on several
advisory boards. Between 1991 and 2000, Ms. Howson was the Senior
Vice President and Director of Worldwide Business Development for
SmithKline Beecham. During her tenure at SB, she and her team
signed numerous in- and out-licensing agreements and research
collaborations. Between 1998 and 2000 she also managed SB’s
$100MM venture capital fund, SR One, the Corporate Development team,
and was a member of the Corporate Management Team. Between 1991
and 1993, she served as Vice President and Director, Worldwide Business
Development for SmithKline. Before joining SmithKline, Tamar was
Vice President, Venture Investments at Johnston Associates, a venture
capital firm. Before that, she was Director of Worldwide Business
Development and Licensing for Squibb Corporation.
Ms. Howson holds a
Masters of Business Administration from Columbia University, a Masters
of Science from City College of New York and Bachelors of Science in
Chemical Engineering from the Technion in Israel.
Perry Karsen, Senior Vice President, Business Development, Celgene
Perry Karsen is Senior
Vice President, Business Development at Celgene Corporation responsible
for Celgene’s business development, licensing and strategic
collaboration initiatives. Perry joined Celgene from Human Genome
Sciences where he was Senior Vice President, Business
Perry began his career
as a product manager at Abbott Laboratories. He was promoted
through several positions within product and general management,
including assignments in Japan and Europe, and then moved into the role
of Director, Licensing and Acquisitions. Perry assumed the role
of Director, Business Development and Representative Director, Japan at
Genentech where he identified and negotiated numerous business
development relationships in the genomics, drug delivery and
development and combinatorial chemistry areas. Perry then joined
Bristol-Myers Squibb where he held positions as Vice President,
Strategic Business Analysis and Development, Vice President, Corporate
Development, and Senior Vice President, Marketing & Sales, Zimmer,
Inc. Perry went on from Bristol-Myers Squibb to become a General
Partner of Pequot Ventures, where he was responsible for early- and
late-stage healthcare investments in biotechnology and medical
Perry has a Masters of
Management degree from Northwestern University’s Kellogg Graduate
School of Management, a Masters in Teaching of Biology from Duke
University, and a B.S. in Biological Sciences from the University of
Illinois, Urbana. In addition, Perry has over 20 years of
pharmaceutical and biotechnology industry experience.
Dan Tully, Managing Director, Altaris Capital Partners
Mr. Tully is a founding
partner of Altaris with responsibility for sourcing, analyzing,
executing and monitoring private equity transactions. Prior to the
formation of Altaris, Mr. Tully held various positions with Merrill
Lynch, including serving as the firm’s global head of healthcare
equity capital markets. Mr. Tully was previously a member of Merrill
Lynch’s private equity and investment banking groups. Mr. Tully
received a B.S. in Economics from the University of Pennsylvania,
Wharton Undergraduate Program.
Mr. Tully is currently
a board member of the following Altaris portfolio companies: Alterna,
Brim Healthcare, Creganna Limited, JDS Pharmaceuticals, M2S and Sparta
Systems. In addition, Mr. Tully serves as vice chairman of the board of
the Hospital for Special Surgery in New York.
Karen Scott Collins, M.D., M.P.H
Vice President, Quality and Patient Safety, New York-Presbyterian Hospital
Dr. Collins joined
NewYork Presbyterian Hospital in August 2007 as Vice President for
Quality and Patient Safety. In this position, she is responsible for
developing and leading clinical quality improvement and patient safety
work across the five hospital campuses of the Columbia and Cornell
Medical Schools. Immediately prior to this, she served as Deputy
Chief Medical Officer, for the New York City Health and Hospitals.
Dr. Collins has
published articles and reports on trends and experiences with managed
care, women’s health, adolescent health and minority
health. She is the co-editor of two books, Women’s Health: The Commonwealth Fund Survey, and Minority Health in America,
both published by Johns Hopkins University Press. In April 2002,
Dr. Collins received the Healthcare Hero award from the Congressional
Black Caucus. Dr. Collins completed her undergraduate degree in
History of Science at Harvard University, medical school at Cornell
University Medical College, and master of public health degree at
Bloomberg School of Public Health at Johns Hopkins
Dr. Lorna Friedman
VP & Senior Medical Executive for National Accounts, CIGNA
Dr. Friedman is
currently Vice President and Senior Medical Executive in CIGNA
Healthcare. She joined CIGNA in 1998 as Associate Medical Director and
since then has grown through many leadership roles within CIGNA. In her
current role, she is responsible for new business development and
growth in multiple product lines including medical, dental, pharmacy,
behavioral and health management. In addition to her stellar record as
part of the sales team, she has innovated on disease management
solution for some of CIGNA’s larger clients.
She is the clinical
liaison in product for wellness and women and children’s
programs: Healthy Kids Challenge, March of Dimes & Healthy Rewards.
She has represented CIGNA in presenting the firm’s vision on
Health Care and Consumerism attended by who’s who on Wall
St’s sell-side and buy-side analysts. Dr. Friedman has an MBA
from Columbia Business School and MD from New York Medical College.
Michael K. Gusmano
Assistant Professor of Health Policy and Management, Mailman School of Public Health
Dr. Michael Gusmano is
the director of research for the Alliance for Health & the Future
and co-director of the World Cities Project at the International
Longevity Center-USA. Dr. Gusmano’s work has focused on comparing
the health status and use of health and social services for older
persons in such cities as New York, London, Paris, and Tokyo. His other
research interests include politics of healthcare reform, Medicare,
Medicaid, and comparative welfare state analysis. Prior to joining the
ILC, Dr. Gusmano was a senior research associate in the Division of
Health and Science Policy at the New York Academy of Medicine.
Previously, he was a research associate in the Department of
Epidemiology and Public Health, and a lecturer in the Department of
Political Science at Yale University where he conducted research on
healthcare politics and policy. Dr. Gusmano was a post-doctoral fellow
in the Robert Wood Johnson Foundation Scholars in Health Policy program
at Yale University.
J. Brent Pawlecki, MD, MMM
Corporate Medical Director, Pitney Bowes Inc.
Dr. Pawlecki serves as
the Corporate Medical Director, overseeing all health related issues
and services of the organization, including the Pitney Bowes'
award-winning corporate clinics and wellness programs and the Absence
In addition, he serves
as corporate medical consultant and as Chief HIPAA Privacy
Officer. Dr. Pawlecki works closely with the integrated functions
of Disability, Safety, and Worker’s Compensation, as well as the
Health Care Strategy Group and the Crisis Management Team to direct
corporate health and productivity for the global organization.
Currently, he is heading the efforts of the global Pandemic
Preparedness Team for the corporation.
Pharmaceutical Marketing Panel:
Moderator: Jacques Mulder
Principal, Deloitte Consulting
Jacques Mulder has been
a Principal at Deloitte Consulting for 4 years in the Healthcare Life
Sciences practice. With years of consulting experience, Jacques
has advised pharmaceutical and biotechnology companies, medical device
manufacturers, healthcare associations, investment firms, and
government organizations. He has developed marketing strategies
for new products, covering issues such as clinical development
strategy, pricing, positioning, and economic evidence needed to support
coverage and optimal payment. Prior to Deloitte, Jacques served
as the head of Quintiles Strategic Research Services, having
responsibility for the Phase IIIb and Phase IV clinical operations,
North America and Canada. He joined Quintiles Strategic Research
Services after having served as Senior Vice President of Quintiles
Integrated Strategic Solutions, Quintiles’ medical communications
and healthcare consulting unit. In this capacity, Jacques was
responsible for market and financial strategy and new business
development where he was personally responsible for revenues in excess
of $80M annually.
Jacques has been
integrally involved in many functional areas of the pharmaceutical
industry including distribution management, strategic management, and
informatics. He has extensive experience across the commercial aspects
of the pharmaceutical industry having worked for several international
pharmaceutical companies. Jacques also has experience in many
therapeutic areas including respiratory, gastrointestinal, and
anti-infective pharmaceuticals and speaks frequently at seminars both
to and for pharmaceutical companies. He is a member of the
International Institute of Marketing Management and speaks at industry
conferences for Frost and Sullivan, PMT, British Biotech Association
and has served as a guest lecturer for EBS at some international
events. Jacques holds a Master of Business Administration from
Edinburgh Business School and a Bachelor of Science in Physiology and
Biomechanics from Clemson University and the University of Pretoria.
Robert Bazemore, Jr.
VP Bio-Worldwide, Johnson & Johnson Pharma Services
Rob Bazemore, with over
16 years of pharmaceutical experience, has served as Worldwide Vice
President - Immunology Franchise, WW Strategic Marketing for Johnson
and Johnson Pharmaceutical Services, since 2005. In this role, Rob
develops the business and portfolio strategy for the J&J Immunology
Franchise, leading implementation of the strategy through Discovery,
Clinical Research and Development, Business Development, and brand
teams. Rob joined Centocor, and Johnson and Johnson company, in 2002
where he led the development and execution of the lifecycle strategy
for REMICADE across therapeutic areas; in 2003, he accepted a position
leading the marketing of REMICADE in Centocor's Rheumatology
Prior to Centocor, Rob
worked for nearly 10 years at Merck from 1991 – 2000.
While at Merck, he broadened his understanding and leadership in
pharmaceuticals through roles in field sales, then medical affairs, and
both brand and strategic marketing.
Rob holds an MBA from Tulane University and a B.A. in biochemistry from the University of Georgia.
Charles G. Beever
Vice President, Booz Allen Hamilton
Mr. Beever is a Vice
President with Booz Allen Hamilton, with over 20 years of experience
working with pharmaceutical and medical products companies to resolve
strategic, organization and performance improvement issues. He
leads Booz Allen Hamilton’s worldwide pharmaceutical practice.
Mr. Beever has worked
with U.S., European, and Japan-based pharmaceutical, biotechnology,
diagnostic and medical device/supply companies on strategic issues
involving business growth, diversification and acquisition due
diligence. He has also led major merger integration planning and
implementation assignments. In addition, he has helped health
care companies redesign their operations and organizations to meet the
needs of the evolving health care environment, yielding significant
improvements in effectiveness and cost.
Mr. Beever holds a BA
degree in economics from Haverford College, where he was elected to Phi
Beta Kappa, and an MBA from the Harvard Graduate School of Business
Senior Vice President, General Manager, Powers (CNS/APM), Pfizer
Andreas Fibig is a
pharmaceutical industry business leader, with more than 20 years
international experience, including executive responsibilities in North
America, South America, Europe and Asia. He has held senior
positions across a broad range of disciplines, from product and brand
management, to sales management, strategic marketing, and both country
and continental leadership.
As Senior Vice
President/General Manager, Powers – CNS/APM, Andreas is
responsible for all of Pfizer’s central nervous system, neurology
and pain management operations in the United States. This
business unit represents some $5 billion in annual revenues, and more
than 4,000 Pfizer colleagues.
Prior to his
appointment as a U.S. business unit head, Andreas served as President
– Latin America/Africa/Middle East, and as Regional President
– Latin America. He had previously been President and
Country Manager for Pharmacia in Germany, after rising through a series
of progressively more senior roles, in Europe and internationally, for
Pharmacia, Boehringer-Ingelheim and Schering.
particular emphasis on long-term planning, innovation across all
functional areas, and the establishment of ethical, mutually-beneficial
partnerships with customers and health care stakeholders. He has
a record of generating successful results in both highly-competitive
developed markets and emerging markets with limited resources.
Throughout his career, he has also devoted major investment and
interest to people development, making the recognition, reward and
promotion of talent a top priority – and a key success factor -
among his teams.
education combined studies in both science and business. He
earned an undergraduate degree in Industrial Chemistry from State
Business School in Berlin, Germany, and a graduate degree in Marketing
and Business Management from Berlin’s University of
He is a member of the
Board of Directors of the non-profit Council of the Americas, and
speaks frequently on international health care trends and developments,
to select groups of health professionals and industry executives.
Fluent in English, German and Spanish, he is co-author of Strategies for Pharma Management,
published in Germany. Andreas lives with his wife, Corina,
a PhD chemist, and two young children in Westchester County, New York.
Richard Johnson, MD, Managing Partner, Hudson
Dr. Richard Johnson is an accomplished life
sciences executive who has held executive marketing, corporate development, and
operating positions with numerous bio-pharmaceutical and health care services
companies. Dr. Johnson is also a prolific entrepreneur, having started seven
highly successful life sciences businesses, and the author of several
publications and patents.
Dr. Johnson recently founded Hudson Medical
Communications (“Hudson”) a full service medical marketing company; MedIQ, a
continuing medical education (CME) company; and Hudson BioScience, a late phase
clinical research business. In addition, he founded Performax (2004), a
physical therapy, rehabilitation, and sports training clinic. While all of
these companies remain private, each of them is profitable and on track for a
Previously, Dr. Johnson was the CEO of Quintiles
Commercialization North America, a group of Quintiles subsidiaries which had
combined revenues of over $300 million at the time of his departure. As CEO,
Dr. Johnson executed a highly successful turnaround, taking the company from a
substantial loss in 2001 to record-setting profit margins within one year. In
his role, Dr. Johnson was also involved in investments made by Quintiles’
corporate venture arm, PharmaBio Development. Prior to becoming CEO of
Quintiles Commercialization, Dr. Johnson was CEO of Quintiles Integrated
Strategic Solutions and Quintiles Medical Communications. Previously, he was a
founder of Q.E.D. Communications, a strategic medical communications firm which
was acquired by Quintiles Transnational.
Dr. Johnson’s experience also includes senior positions
in clinical research, medical education, new product development, and marketing
at Lederle Laboratories (now Wyeth Pharmaceuticals), a Fortune 500
pharmaceutical company. During that time, he executed co-promotional deals and
licensing agreements, conducted technology assessments and market forecasts,
and successfully launched several new products with strong intellectual
property claims into highly competitive, multibillion dollar markets. Dr.
Johnson formerly practiced internal and critical care medicine and was a
General Partner in the Genesis Fund I, a technology venture capital fund
located in Houston, Texas.
He earned a bachelor’s degree (Phi Beta Kappa) from
New York University and a medical degree from
Mount Sinai School of Medicine. In addition, he received graduate business
training from Columbia
Management Training Program.
Phillip M. Satow
Phillip has more than 35 years of experience in the pharmaceutical
industry. He was Executive Vice President of Forest Laboratories, Inc.
where he oversaw all marketing and sales functions, was President of
Forest Pharmaceuticals and a former member of its Board of Directors.
For 15 years as head of sales and marketing for Forest, Phillip built
the Company's sales and marketing infrastructure and retired soon after
launching Forest's successful anti-depressant, Celexa. Prior to joining
Forest, he served for three years as Vice President and General Manager
of the Wallace Laboratories Division of Carter-Wallace, Inc. He held a
variety of executive positions at Pfizer, Inc. over a 14 year period,
including Director of Marketing, Pfizer Laboratories, and Vice
President, Pfizer Europe. Most recently Phillip founded JDS
Pharmaceuticals LLC along with his son Michael. The company was
recently purchased by Noven Inc. Phillip currently serves on the board
of directors of Crucell Inc. and Noven Inc., both public companies,
holds a B.A. from Columbia College and an M.A. in Economics from
Emerging Markets Panel
Amanda Heron Parsons MD, MBA
Engagement Manager, McKinsey
Amanda Heron is an Engagement Manager in
McKinsey’s New York office exclusively focused on the Healthcare
Sector. Since joining the Firm in 2003, she has served the
Pharmaceutical & Medical Products practice as well as the
Payor/Provider and Global Public Health practices, and has worked in
strategy, marketing, product valuation, R&D business plan
formulation, and operations improvement.
Amanda serves on the
Board of VIP Community Services and is on the Young Leadership Council
of the TOUCH foundation. Prior to joining McKinsey,
Amanda’s work experiences include a Project Specialist position
at Theradex, Inc, a CRO in Princeton NJ, focused on preparing drug
filings in the Oncology market, and a Business Development position at
Warren Pharmaceuticals, a start-up biotech company in Ossining NY,
focused on preparing the company’s business plan for the
Amanda earned her M.D.
from Columbia University, College of Physicians and Surgeons. She
also holds an MBA from Columbia’s Graduate School of Business,
where she majored in Management. Amanda recently took a one-year leave
of absence to do her internship in Internal Medicine at Beth Israel
Medical Center to become a licensed physician.
VP External Research, Eli Lilly
Robert W. Armstrong,
Ph.D., became vice president of global external research and
development for Eli Lilly and Company in November 2006. He previously
was vice president of discovery chemistry research. Armstrong's new
position will serve to accelerate LRL's ability to access external
innovation, including scientific and medical capabilities and capacity,
as well as new drug candidates. He is also a member of the senior
Prior to joining Lilly in November 1999, Armstrong had been director and head of small molecule drug discovery at Amgen, Inc.
Born in Texas and
raised in Latin America, Armstrong speaks fluent Spanish. He received
bachelor of science degrees in chemistry and biochemistry from the
University of California at San Diego in 1979 and a doctorate degree in
chemistry from Colorado State University in 1984. Upon completion of an
NIH postdoctoral fellowship with Yoshito Kishi at Harvard University,
he joined the University of California at Los Angeles faculty in 1986
as an assistant professor.
efforts have concentrated on the areas of total synthesis of natural
products, development of synthetic methodology, and synthesis and
conformational analysis of natural and synthetic biopolymers, including
DNA, peptides, and oligosaccharides. A second area of interest includes
the eludication of the mechanism of action of DNA modifying agents and
the design of nucleoside modifications as structure-activity probes.
He received an NSF Presidential Young Investigator Award in 1988 and a Sloan Foundation Fellowship in 1990.
David Epstein (’87)
President and CEO, Novartis Oncology
David R. Epstein is
President & CEO, Novartis Oncology. In this position, he is
responsible for leading Novartis’ global Oncology Business Unit,
one of the world’s top Oncology companies with five key marketed
products – Glivec, Femara, Zometa, Sandostatin LAR and Exjade
– and a leading pipeline recognized as exceptionally broad and
deep. In 2006, Novartis Oncology’s sales grew 15.5% to
$5.9bio and market share grew to 9.8%.
oversees a staff of more than 4,300 employees operating in over 50
countries. He is a member of Novartis AG’s Pharma Committee
and Pharmaceutical Executive Committee.
Epstein has held a
series of positions of increasing responsibility since joining the
company as a new product manager with Sandoz in 1989. Epstein
most recently served as CEO, Novartis Specialty Medicines, overseeing
the global Ophthalmics and Transplantation & Immunology Business
Units in addition to his responsibilities leading Novartis Oncology. He
previously served as Chief Operating Officer of Novartis
Pharmaceuticals Corporation in the U.S and has held several positions
in marketing and general management. During the planning process
that resulted in the 1996 merger of Ciba-Geigy Ltd. and Sandoz Ltd.,
Epstein co-chaired the U.S. and Canadian Pharma Steering Committees as
the Integration Officer, North America. In January 1997, he was
promoted to Vice President, Marketing and Sales, Specialty Business
Sector, responsible for U.S. business units focused on Oncology and
Transplant/Immunology/Tissue Engineering. Prior to joining the
company, he was an associate in the Strategy Practice of consulting
firm Booz, Allen and Hamilton.
Epstein holds a B. S.
degree in Pharmacy with high honors from Rutgers University College of
Pharmacy and an M.B.A. in Finance and Marketing from the Columbia
University Graduate School of Business.
Joseph R. Flicek
Managing Director, Amphion Innovations
Joe Flicek is a
Managing Director of Amphion Innovations in their New York
Office. Amphion's business is the formation, financing,
management and development of life science and technology companies.
He specializes in taking these new technologies and
under-performing assets and leveraging and enhancing their intellectual
property and business assets into profitable company building
opportunities. Amphion Portfolio Companies are broad-based,
proprietary, platform technologies in the areas of pharmacogenomics,
nutriceuticals, diagnostics, medical products and related fields,
leveraging advances in semiconductors, RFID technologies and life
science IT technologies.
He currently serves on
the boards of FireStar Software, Inc. and M2M Inc, who are Amphion
partner companies. Mr. Flicek created and established the New
Ventures group of the Science & Technology Ventures Office at
Columbia University in 1996. Under his leadership Columbia
participated in the formation of over 30 new University spin-outs, four
of which are publicly traded. Mr. Flicek is an adjunct faculty member
of Columbia University’s Graduate Business School in
Entrepreneurship and assists faculty and students in startup businesses
through entrepreneurship programs.
Standard & Poor’s Healthcare Economics and Policy Industry Leader www.healthcare-economics.org
Dr. David Gershon has
over 20 years experience as a physician, clinical trial investigator,
healthcare regulatory attorney, and global healthcare economics and
policy advisor with expertise in legislative and regulatory affairs,
intellectual property, CMS and private payor pricing/reimbursement, and
FDA drug and medical device approval processes. Dr. Gershon currently
serves as the Chairman of the National Institute for Healthcare
Economics and Regulatory Policy, is a designated Standard & Poor's
'Industry Leader', and serves as advisor to the Goldman Sachs Principal
Strategies Group on matters pertaining to global healthcare economics,
finance and policy.
Dr. Gershon is
recognized for his ability to take a broad look at global legislative,
regulatory, and economic changes that affect medical research, drug
approval, cost effectiveness, and access to healthcare in the US,
Brazil, Russia, India, China, and South Africa and to translate these
changing dynamics into models for investment firms and healthcare
policy legislators. Of particular interest are large pharmaceutical,
biotechnology, generics, and healthcare services companies that either
leverage advantages or seek to mitigate damages from these changes.
Over the past 10 years
Dr. Gershon has been a senior level advisor for a number of blue chip
investment firms, corporations, and legislators including Goldman
Sachs, Merrill Lynch, Bain Capital, Schroders, Fidelity Investments,
AIG, Publicis, American Express, Bristol-Myers Squibb, GlaxoSmithKline,
Texas Pacific Group, Senator John Kerry, Senator John Edwards, and
former Attorney General Elliot Spitzer, providing in-depth insights
into the increasingly important interaction between medical and
scientific advancements and regulatory, legal, and economic changes
that affect global healthcare market dynamics and competitive
landscapes, including changes in drug discovery, medical research and
development, FDA approval processes, pricing, reimbursement,
intellectual property, and clinical and commercial market applications
for new drugs and devices.
Dr. Gershon has
published and lectured widely on healthcare economics, innovation and
drug discovery, and healthcare policy. He holds several academic
appointments and teaches at business schools in North America and
Europe about how scientific innovation and global regulatory changes
are driving new business models whose dynamics and creative
partnerships are opening new investment opportunities in the
pharmaceutical, biotechnology, medical device, healthcare services, and
generic pharmaceutical industries.
Dr. Gershon is
currently an Adjunct Professor of Healthcare Economics and Policy at
Johns Hopkins University, Dept of Advanced Biotechnology/MBA Program;
Visiting lecturer of Healthcare Economics and Drug Development at
Harvard University; Visiting Scholar Lecturer of Healthcare Economics
and Policy at McGill University; and has been a guest lecturer at
Oxford University, New York University, and Columbia University.
As part of his social
commitment Dr. Gershon is assisting in the design and development of
public-private partnerships between policy makers, corporations,
foundations, financial firms, and social entrepreneurs that target
healthcare disparities and promote innovation in drug R&D, access
He is particularly
focused on advancing public-private partnerships that develop future
leaders who are committed to developing businesses that address
healthcare disparities in minority women and children in the U.S. and
infrastructure, sustainability and capacity building barriers facing
HIV/AIDS, Malaria, and TB care and treatment programs for women and
children in Africa and developing countries.
He is writing a book
and has designed a series of seminars entitled, "Future Scenarios:
Charting a Course in the New Global Healthcare Economy" which defines
the role government and public-private partnerships have in shaping
healthcare and catalyzing social change in our global economy and
provides a practical resource for decision makers to help drive more
cost effective, socially responsible utilization of healthcare
Dr. Gershon received
his Doctorate in Jurisprudence and Masters Degree in Public Health from
Boston University where he specialized in healthcare regulatory law,
economics and healthcare policy and his Doctorate in Medicine from
McGill University and Post-Doctoral training from New York Presbyterian
Medical Center and Memorial Sloan-Kettering Cancer Center. He is the
recipient of the Memorial Sloan-Kettering Cancer Center Mayday
Fellowship in oncology pain management, the Ciba-Geigy Outstanding
Researcher Award, and the Boston University Public Interest Grant.
General Manager, Diagnostic Imaging Performance Technologies
Joe leads a section of
GE’s Diagnostic Imaging business focused on value products and
solutions for customers around the world.
Technologies includes the GoldSeal refurbished and remanufactured
products business and the Primary Care emerging markets business.
The mission of these businesses is to provide high-quality, affordable
Diagnostic Imaging systems to customers whose needs are great but whose
budgets are not.
Joe has been in GE
Healthcare since 2001. Following an assignment as Six Sigma
Quality Leader for the Americas Diagnostic Imaging business, he was
appointed as General Manager of GoldSeal in 2003. In 2005 his
role was expanded to include Primary Care for emerging markets as
Performance Technologies GM.
Before coming to
Healthcare, Joe spent 15 years in a variety of other GE businesses and
positions, most recently as Managing Director of GE Quartz Europe from
1999 to 2001 and GE Quartz Asia Pacific Operations GM from 1995 to 1998.
Joe earned a Bachelor
of Science in Economics degree from the Wharton School and a Bachelor
of Science in Electrical Engineering from the Moore School, both at the
University of Pennsylvania, in 1986.